SCHEMBL7004973

SCHEMBL7004973

COCC(=O)Nc1cccc([N+](=O)[O-])c1

nearest known ligand 0.71

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 8/20 0.71
KMT2A Q03164 8/20 0.71
HTT P42858 3/20 0.67
ALDH1A1 P00352 7/20 0.64
SMN1; SMN2 Q16637 2/20 0.64
POLB P06746 3/20 0.63
MAPT P10636 5/20 0.63
DDX3X O00571 1/20 0.63
CTDSP1 Q9GZU7 1/20 0.63
L3MBTL1 Q9Y468 1/20 0.61
LMNA P02545 1/20 0.61
MAPK1 P28482 2/20 0.60
HSP90AA1 P07900 1/20 0.60
HPGD P15428 1/20 0.60
CACNA1B Q00975 1/20 0.60
APBA1 Q02410 1/20 0.60
NPSR1 Q6W5P4 1/20 0.60
NLRP1 Q9C000 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3217135 0.88 MEN1 (0.64) MEN1KMT2AHTTALDH1A1SMN1; SMN2
SCHEMBL13488642 0.86 HTT (0.76) MEN1KMT2AHTTALDH1A1SMN1; SMN2
SCHEMBL6159248 0.86 MEN1 (0.80) MEN1KMT2AHTTALDH1A1SMN1; SMN2
SCHEMBL10876285 0.85 MEN1 (0.58) MEN1KMT2AHTTALDH1A1SMN1; SMN2
SCHEMBL5141415 0.85 MEN1 (0.75) MEN1KMT2AHTTALDH1A1SMN1; SMN2
SCHEMBL4186398 0.84 HTT (0.62) MEN1KMT2AHTTALDH1A1SMN1; SMN2
SCHEMBL5213509 0.84 CYP1A2 (0.78) MEN1KMT2AHTTALDH1A1SMN1; SMN2
SCHEMBL30957465 0.84 CYP1A2 (0.78) MEN1KMT2AHTTALDH1A1SMN1; SMN2
SCHEMBL9495103 0.83 SMN1; SMN2 (0.71) MEN1KMT2AHTTALDH1A1SMN1; SMN2
SCHEMBL8752436 0.82 SMN1; SMN2 (0.72) MEN1KMT2AHTTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113185417-B Red base B separation process 山东师范大学实验厂有限公司 2022-12-20 CN claimed
CN-113185417-A Red base B separation process 山东师范大学实验厂 2021-07-30 CN claimed
US-20240408064-A1 RAS INHIBITORS, COMPOSITIONS AND METHODS OF USE THEREOF GENETOLEAD INC. (CA) 2024-12-12 US disclosed
WO-2023060362-A1 RAS INHIBITORS, COMPOSITIONS AND METHODS OF USE THEREOF GENETOLEAD INC. (CA) 2023-04-20 WO disclosed
CN-113185417-B Red base B separation process 山东师范大学实验厂有限公司 2022-12-20 CN disclosed
CN-113185417-B Red base B separation process 山东师范大学实验厂有限公司 2022-12-20 CN disclosed
CN-113185417-A Red base B separation process 山东师范大学实验厂 2021-07-30 CN disclosed
CN-113185417-A Red base B separation process 山东师范大学实验厂 2021-07-30 CN disclosed
US-20080166310-A1 Administration of 2-oxyacetamide compounds for promoting and/or inducing and/or stimulating the pigmentation of keratin materials and/or for limiting the depigmentation and/or bleaching thereof L'OREAL (FR) 2008-07-10 US disclosed
EP-1268487-B1 TRICYCLIC PROTEIN KINASE INHIBITORS WYETH CORP (US) 2003-11-26 EP disclosed
US-6608048-B2 Treatment of cancer, polycystic kidney disease and colonic polyps in mammals WYETH HOLDINGS 2003-08-19 US disclosed
US-5631209-A ALGICIDES ROHM AND HAAS COMPANY (US) 1997-05-20 US disclosed
US-5502027-A ALGICIDES ROHM AND HAAS COMPANY (US) 1996-03-26 US disclosed
EP-0415642-B1 Glutarimides ROHM & HAAS (US) 1995-12-06 EP disclosed
US-5393735-A N-(halo-oxy-)phenyl substituted cyclic imides ROHM AND HAAS COMPANY (US) 1995-02-28 US disclosed
EP-0415641-B1 Substituted glutaramic acids and derivatives ROHM & HAAS (US) 1994-01-19 EP disclosed
US-5238908-A HERBICIDAL GLUTARAMIC ACIDS AND DERIVATIVES ROHM AND HAAS COMPANY (US) 1993-08-24 US disclosed
EP-0415641-A1 Substituted glutaramic acids and derivatives ROHM AND HAAS COMPANY (US) 1991-03-06 EP disclosed
EP-0415642-A1 Glutarimides ROHM AND HAAS COMPANY (US) 1991-03-06 EP disclosed
US-4025642-A ANTIALLERGENS SMITHKLINE CORPORATION (US) 1977-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240408064-A1 RAS INHIBITORS, COMPOSITIONS AND METHODS OF USE THEREOF KRAS, NRAS, HRAS MEN1 671/4885KMT2A 2133/4885HTT 2241/4885
US-20080166310-A1 Administration of 2-oxyacetamide compounds for promoting and/or inducing and/or stimulating the pigmentation of keratin materials and/or for limiting the depigmentation and/or bleaching thereof KRT18, TYR, CRYAA MEN1 4421/4885KMT2A 82/4885HTT 2181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.